ReviewCureus2026
Innovations in the Treatment of Antibiotic-Resistant Infections in Internal Medicine.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is one of the major contemporary challenges in internal medicine, impairing the effectiveness of empirical antibiotic regimens and increasing mortality, hospital length of stay, and healthcare costs. The rising prevalence of multidrug-resistant Gram-negative organisms calls for a clinical response grounded in therapeutic innovation, antimicrobial rationalisation, and institutional reorganisation. We conducted a narrative review of the literature from 2020 to 2025, integrating recommendations from international guidelines, including the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), epidemiological data from the European Centre for Disease Prevention and Control (ECDC) and the Portuguese PPCIRA (Programa de Prevenção e Controlo de Infeções e de Resistência aos Antimicrobianos) programme, and institutional implementation examples from Portuguese hospitals. Several newly approved antibiotics were identified with documented efficacy against resistant pathogens (e.g., ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol), along with promising therapeutic approaches such as bacteriophage therapy and immunomodulation. Clinical decision support tools (algorithms, dashboards, checklists) and institutional models demonstrated positive impact on key indicators such as time to active therapy, de-escalation rates, and reduced use of reserve antibiotics. Managing resistant infections in internal medicine requires an integrated, patient-centred approach supported by updated evidence. Internists must take a strategic role in therapeutic decision-making, clinical governance, and the implementation of tailored protocols, actively contributing to AMR containment and improved clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.